临床试验中的适应性设计:从科学建议到欧洲药品管理局上市许可
该研究追踪了59项曾向欧洲药品管理局(EMA)科学建议(SA)提交过适应性设计的确认性临床试验,分析其启动、完成、结果及对上市许可的影响。适应性设计在药物开发中已确立,需早期监管对话并控制I类错误率。
要点
- 适应性设计需预先规划并早期与监管机构沟通。
- 中期分析可因无效而提前终止试验,节省资源。
- I类错误率控制、试验完整性和结果一致性是关键。
核心结论
- 适应性设计在药物开发中已确立,适当预规划可帮助成功选择剂量方案。
- 中期分析可因无效而终止试验,避免资源浪费。
- I类错误率控制、试验完整性和各阶段结果一致性是必须充分讨论的基本方面。
- 强烈建议早期与监管机构对话并实施所收到的科学建议。
研究设计与样本
- 基于EMA内部上市许可申请数据库、AdisInsight数据库和相关试验注册库,追踪59项曾提交EMA科学建议的适应性试验。
- 分析试验启动、完成状态、结果、启动时间、最终实施的适应性要素及其对试验成功和产品批准的影响。
主要发现
- 23项完成试验中9项(39%)主要终点显示显著治疗效应,4项(17%)支持上市许可。
- 另有两项试验因预设无效标准而停止,有效识别不应继续投入资源的试验。
- 从EMA科学建议信发出到试验启动的中位时间为5个月。
- 在试验注册库中,至少18项试验(31项中的58%)实施了适应性要素,主要为剂量选择、样本量重估(SSR)和无效停止(SFF)。
临床怎么用
- 在确认性试验中考虑适应性设计时,应预先规划并充分讨论I类错误率控制、试验完整性和结果一致性。
- 建议早期与监管机构进行对话并实施科学建议,以积累的讨论和评估经验支持适应性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, experience on the application of adaptive designs in confirmatory clinical trials has accumulated. Although planning such trials comes at the cost of additional operational complexity, adaptive designs offer the benefit of flexibility to update trial design and objectives as data accrue. In 2007, the European Medicines Agency (EMA) provided guidance on confirmatory clinical trials with adaptive (or flexible) designs. In order to better understand how adaptive trials are implemented in practice and how they may impact medicine approval within the EMA centralised procedure, we followed on 59 medicines for which an adaptive clinical trial had been submitted to the EMA Scientific Advice (SA) and analysed previously in a dedicated EMA survey of scientific advice letters. We scrutinized in particular the submission of the corresponding medicines for a marketing authorisation application (MAA). We also discuss the current regulatory perspective as regards the implementation of adaptive designs in confirmatory clinical trials. METHODS: Using the internal EMA MAA database, the AdisInsight database and related trial registries, we analysed how many of these 59 trials actually started, the completion status, results, the time to trial start, the adaptive elements finally implemented after SA, their possible influence on the success of the trial and corresponding product approval. RESULTS: Overall 31 trials out of 59 (53%) were retrieved. Thirty of them (97%) have been started and 23 (74%) concluded. Nine of these trials (39% out of 23) demonstrated a significant treatment effect on their primary endpoint and 4 (17% out of 23) supported a marketing authorisation (MA). An additional two trials were stopped using pre-defined criteria for futility, efficiently identifying trials on which further resources should not be spent. Median time to trial start after SA letter was given by EMA was 5 months. In the investigated trial registries, at least 18 trial (58% of 31 retrieved trials) designs were implemented with adaptive elements, which were predominantly dose selection, sample size reassessment (SSR) and stopping for futility (SFF). Among the 11 completed trials including adaptive elements, 6 demonstrated a significant treatment effect on their primary endpoint (55%). CONCLUSIONS: Adaptive designs are now well established in the drug development landscape. If properly pre-planned, adaptations can play a key role in the success of some of these trials, for example to help successfully select the most promising dose regimens for phase II/III trials. Interim analyses can also enable stopping of trials for futility when they do not hold their promises. Type I error rate control, trial integrity and results consistency between the different stages of the analyses are fundamental aspects to be discussed thoroughly. Engaging early dialogue with regulators and implementing the scientific advice received is strongly recommended, since much experience in discussing adaptive designs and assessing their results has been accumulated.
引用
- Collignon O, Koenig F, Koch A, et al. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency. Trials. 2018. PMID: 30454061. doi:10.1186/s13063-018-3012-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。